For first-time users, start with a gentle formulation containing 0.5-1% glutathione along with moisturising ingredients
Example Scenario: A provider administers a corticosteroid injection for a condition not listed as covered in the payers medical necessity guidelines
There is insufficient evidence to determine whether NAD+ supplementation influences glucose homeostasis in clinically meaningful ways, but patients should maintain regular glucose monitoring as recommended by their healthcare provider
When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
PMCID: PMC7108996 Andersen NB, Malmlf K, Johansen PB, Andreassen TT, rtoft G, Oxlund H